ArticleRSC advances2025
Simultaneous conversion of dialkyl phosphites to dialkyl phosphoric acids and SeO
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel, very simple, one-way, economical, and convenient reaction method for the simultaneous synthesis of dialkyl phosphoric acids and selenium nanoparticles has been developed. This communication describes the synthesis and characterization of selenium nanoparticles through the reactions of dialkyl phosphites and selenium dioxide. Dialkyl phosphites serve as reducing agents for converting selenium dioxide (a hazardous selenium source) to selenium nanoparticles (Se NPs), and conversely, selenium dioxide oxidizes dialkyl phosphites to dialkyl phosphoric acids. The impact of solvents, temperature, and ratio of materials is included in this study. Most of the prepared Se NPs tend to agglomerate, and their stability improved by the addition of β-cyclodextrin. In addition to enhancing the stability of Se NPs by cyclodextrin, the anticancer properties of the as-prepared Se NPs stabilized by β-cyclodextrin are studied. The reported method presents the conversion of selenium dioxide (a hazardous selenium source) to valuable Se NPs (hemispherical Se crystals) and industrially applicable dialkyl phosphoric acids from inexpensive materials with zero E factor and one atom economy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.